Risk factors for starting lipid-lowering therapy during the FIELD study.^*

*Model derived by using the placebo group only. †Patients who had started using statins, fibrates, resins or other lipid-lowering medications during the trial and had remained on them for at least 3 months in total. ‡The initial variables were: sex, age, country, clinical history (myocardial infarction, stroke, angina, CABG, PTCA), smoking status, BMI, waist–hip ratio, systolic blood pressure, diastolic blood pressure, LDL cholesterol, HDL cholesterol, triglyceride. FIELD = Fenofibrate Intervention and Event Lowering in Diabetes; HR = hazard ratio; CI = confidence interval; PTCA = percutaneous transluminal coronary angioplasty; BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein.